Testing for allergic diseases refers to the detection of substances that cause allergies, i.e., allergens. Finding out whether a patient is allergic, to what allergen he or she is allergic, and to what extent, is extremely important for guiding the patient to targeted prevention and specific treatment. Currently, allergen detection methods include in vivo and in vitro testing. In vivo testing is a specific diagnostic method in which a small amount of allergen purification is injected into the body, or in contact with the skin or mucous membranes, and then the reaction is observed. It includes skin test, nasal mucous membrane, conjunctival test, etc. At present, the most widely used in clinical practice is the skin test. There are also several different methods of skin testing, such as intradermal injection, puncture, spot patch and other methods. The principle is basically the same, among which the most widely used and reliable results are the intradermal test method and the prick test method, the principle is to inject or prick a small amount of allergen substance into the skin, if the substance is allergic, then after a period of time, the skin will appear mounds of wind, red spots, etc., the more obvious it is, the more serious the degree of allergy. Because the prick method is safer, less painful and more acceptable to patients than the intradermal test, there has been a trend in recent years to replace the intradermal test with the prick method. In vitro testing is a method of detecting allergies by testing the serum allergy antibody sIgE. sIgE, also known as specific IgE, is a special allergy antibody produced by allergic patients after exposure to allergens, and each allergen induces a different sIgE. sIgE is the culprit of allergic reactions. The higher the level and more types of sIgE detected in the test results, the more severe the allergy is. Since allergic diseases are caused by a series of reactions caused by IgE in the body that lead to the occurrence of various allergic symptoms, sIgE testing can better reflect the immune status of the body in which the allergy occurs. Especially when desensitization treatment is needed, the level of sIgE in the body is very important for predicting whether desensitization is needed and the efficacy of desensitization. The observation of sIgE changes in the body after desensitization therapy is also very important for the evaluation of the efficacy and later treatment planning. Currently, there is a wide range of reagents for in vitro testing, including qualitative and quantitative assays. The internationally recognized “gold standard” for sIgE testing is the CAP allergen detection system from Farmacia, Sweden. In comparison with in vitro testing, in vivo testing is influenced by a number of factors, such as age, children and the elderly are generally less sensitive to skin reactions, so the skin test reflects a relatively low degree of allergy; in addition, the skin test is greatly affected by drugs, for example, if the skin test is preceded by anti-allergy drugs, cold medication, the drug must be stopped for a few days before the skin test. However, because the skin test method has been applied for a long time, the method is relatively mature, and the price is low, so it is still not lost as a sensitive and reliable diagnostic method. In vitro testing is relatively less affected by factors, taking anti-allergy drugs will not affect the test results, and the test results are more objective and accurate, in vitro testing undoubtedly has greater superiority than in vivo testing, but because the reagents need to be imported, so the price is relatively expensive, we can only look forward to the development of domestic reagents, in order to make this test better to promote the application.